Core Insights - The article discusses the stock buyback activities of various companies, highlighting the total amounts and quantities repurchased, with Tencent Holdings leading the buyback efforts [1][2]. Group 1: Buyback Overview - Tencent Holdings (00700) repurchased 1.051 million shares for a total of 636 million, representing 0.995% of its total share capital [2]. - Xiaomi Group (01810) repurchased 7.2 million shares for 302 million, accounting for 0.430% of its total share capital [2]. - China COSCO Shipping Holdings (01919) repurchased 2.95 million shares for 40.016 million, which is 3.089% of its total share capital [2]. Group 2: Notable Buybacks - Kuaishou Technology (01024) repurchased 462,000 shares for 29.9304 million, representing 0.191% of its total share capital [2]. - Kingsoft Corporation (03888) repurchased 702,800 shares for 19.9994 million, which is 0.580% of its total share capital [2]. - Country Garden Services (06098) repurchased 3 million shares for 18.9615 million, accounting for 1.284% of its total share capital [2]. Group 3: Other Companies - Coolpad Group (02369) repurchased 3.16 million shares for 4.1717 million, representing 7.986% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 764,000 shares for 3.306 million, which is 0.190% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 200,000 shares for 2.9675 million, accounting for 0.762% of its total share capital [2].

今年以来该股累计进行68次回购，合计回购2544.30万股，累计回购金额1.90亿港元。（数据宝） 和铂医药-B回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.15 | 40.00 | 13.000 | 12.390 | 507.12 | | 2025.12.08 | 20.00 | 13.650 | 12.970 | 267.66 | | 2025.12.05 | 10.00 | 14.250 | 13.630 | 139.92 | | 2025.11.28 | 10.00 | 13.530 | 13.180 | 133.70 | | 2025.11.21 | 20.00 | 12.810 | 12.720 | 255.54 | | 2025.11.18 | 10.00 | 13.720 | 13.620 | 136.82 | | 2025.11.17 | 10.00 | 13.800 | 13.680 | 137.50 | | 2025.11.13 | ...

和铂医药-B(02142)发布公告，于2025年12月15日，该公司斥资507.12万港元回购40万股股份，每股回购 价格为12.39-13港元。 ...

智通财经APP讯，和铂医药-B(02142)发布公告，于2025年12月15日，该公司斥资507.12万港元回购40万 股股份，每股回购价格为12.39-13港元。 ...

格隆汇12月15日丨和铂医药-B(02142.HK)公告，12月15日耗资507.1万港元回购40万股，回购价格每股 12.39-13港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 第 1 頁 共 7 頁 v 1.3.0 | 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | 3). | 20,000 | 0.0023 % | HKD | 0 | | | --- | --- | --- | --- | --- | --- | --- | | | 而發行新股或轉讓庫存股份 - 涉及新股 | | | | | | | 根據於2020年11月23日採納及獲本公司股東批准的首次公開發售後 | | | | | | | | | 股份獎勵計劃而發行普通股以滿足股份獎勵 | | | | | | | | 變動日期 2025年12月10日 | | | | | | | | 4). 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | 11,000 | 0.0013 % | HKD | 0 | | | | 而發行新股或轉讓庫存股份 - 涉及新股 | | | | | | | | 根據於2020年11月23日採納及獲本 ...

Group 1 - Hong Kong pharmaceutical stocks experienced a general decline, with notable drops in share prices [1] - Gilead Sciences-B (01672.HK) fell by 11.02%, trading at HKD 12.92 [1] - Saint Noble Pharmaceuticals-B (02257.HK) decreased by 8.27%, with a price of HKD 8.32 [1] - Hengrui Medicine-B (02142.HK) saw a decline of 7.29%, priced at HKD 12.46 [1] - Rongchang Biopharmaceutical (09995.HK) dropped by 4.87%, now at HKD 75.15 [1]

Group 1 - The pharmaceutical sector is experiencing a general decline, with notable drops in stock prices for companies such as Genscript Biotech (down 11.02% to HKD 12.92), Sanofi (down 8.27% to HKD 8.32), and others [1] - Haitong International's research report indicates that the recent pullback in the pharmaceutical sector is primarily due to seasonal factors affecting liquidity, particularly the year-end accounting by southbound funds [1] - The report highlights a decreasing proportion of holdings in leading pharmaceutical stocks within the Hong Kong Stock Connect, such as Innovent Biologics and China National Pharmaceutical Group [1] Group 2 - Despite the short-term challenges, the report maintains a positive long-term outlook for the innovative drug industry chain, particularly for companies with strong fundamentals and successful overseas clinical progress [1] - The focus is on companies with strong earnings certainty in internet healthcare, CXO/research services, and leading biotech and pharmaceutical firms that have established external collaborations [1]

Core Viewpoint - The pharmaceutical sector is experiencing a general decline, with significant drops in stock prices for various companies, attributed to seasonal factors affecting liquidity and southbound fund flows [1] Group 1: Market Performance - Major pharmaceutical stocks have seen substantial declines, with Gilead Sciences-B (01672) down 11.02% to HKD 12.92, Sanofi-B (02257) down 8.27% to HKD 8.32, and Hengrui Medicine-B (02142) down 7.29% to HKD 12.46 [1] - Overall, the Hong Kong pharmaceutical sector has performed weakly, influenced by seasonal factors such as year-end fund settlement [1] Group 2: Analyst Insights - Haitong International's report indicates that the pharmaceutical sector is under short-term pressure due to liquidity issues, but maintains a positive long-term outlook on the innovative drug industry chain [1] - The report highlights a continuous decline in the Hong Kong Stock Connect holdings of leading pharmaceutical stocks, such as Innovent Biologics and China National Pharmaceutical Group [1] Group 3: Long-term Opportunities - The firm expresses confidence in the long-term prospects of internet healthcare, CXO/research service leaders, and top biotech and pharmaceutical companies that have established external collaborations and are making progress in overseas clinical trials [1]

智通财经APP讯，和铂医药-B(02142)公布，2025年12月8日耗资约267.66万港元回购20万股股份。 ...